Screener
Axsome Therapeutics AXSM Accounts Payable
Accounts Payable at other companies
Other financials
Where this comes from
Reported directly by Axsome Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:AccountsPayableCurrent.
The source filing: Axsome Therapeutics’s 10-Q, filed May 4, 2026.
- Filed
- May 4, 2026, 5:04 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-204274
| Line item | March 31,2026 | December 31,2025 |
|---|---|---|
| Total assets | $713,607 | $689,805 |
| Liabilities and stockholders’ equity | ||
| Current liabilities: | ||
| Accounts payable | $106,702 | $65,537 |
| Accrued expenses and other current liabilities | 250,731 | 232,853 |
| Operating lease liability, current portion | 628 | 434 |
| Contingent consideration, current | 11,150 | 10,012 |
| Short-term borrowings | 70,000 | 70,000 |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is Axsome Therapeutics's accounts payable?
- Axsome Therapeutics (AXSM) reported accounts payable of $106.7M in Q1 2026.
- How has Axsome Therapeutics's accounts payable changed year-over-year?
- Axsome Therapeutics's accounts payable increased by 24.6% year-over-year, from $85.66M to $106.7M.
- What is the long-term trend for Axsome Therapeutics's accounts payable?
- Over 5 years (2020 to 2025), Axsome Therapeutics's accounts payable has grown at a 37.2% compound annual growth rate (CAGR), from $13.5M to $65.54M.
- What does accounts payable mean?
- Amounts owed to suppliers and vendors for goods and services received but not yet paid. A primary source of short-term trade financing.
Ask your AI about Axsome Therapeutics's accounts payable.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude